• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 14, 2024 at 11:12: PM
via Eisai (4523.T) and partner Biogen (BIIB.O) said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi.

article source
 

<



Similar threads

cafead
Eisai, Biogen&#039;s Leqembi nabs UK nod, but reimbursement remains elusive
Replies
0
Views
33
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
After EU setback, Eisai/Biogen build case for Leqembi
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai &#039;extremely disappointed&#039; by EMA&#039;s decision on Alzheimer&#039;s drug
Replies
0
Views
23
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai and Biogen&#039;s Alzheimer&#039;s med Leqembi turned down in Europe
Replies
0
Views
39
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote